about
Current State of Animal (Mouse) Modeling in Melanoma ResearchBeyond BRAF: where next for melanoma therapy?Targeting the VEGF-C/VEGFR3 axis suppresses Slug-mediated cancer metastasis and stemness via inhibition of KRAS/YAP1 signalingMelanoma-infiltrating dendritic cells: Limitations and opportunities of mouse modelsPostnatal lineage mapping of follicular melanocytes with the Tyr::CreER(T) (2) transgeneRAF proteins exert both specific and compensatory functions during tumour progression of NRAS-driven melanoma.A brief history of melanoma: from mummies to mutationsThe current state of targeted therapy in melanoma: this time it's personalA murine model for the development of melanocytic nevi and their progression to melanoma.Whole recombinant yeast vaccine induces antitumor immunity and improves survival in a genetically engineered mouse model of melanoma.Genetics of melanomaThe dysplastic nevus: from historical perspective to management in the modern era: part I. Historical, histologic, and clinical aspectsTargeting mutant NRAS signaling pathways in melanoma.Human skin neural crest progenitor cells are susceptible to BRAF(V600E)-induced transformationGAB2 induces tumor angiogenesis in NRAS-driven melanoma.NRAS mutant melanoma: biological behavior and future strategies for therapeutic management.Primary melanoma of the CNS in children is driven by congenital expression of oncogenic NRAS in melanocytes.Animal models of melanoma: a somatic cell gene delivery mouse model allows rapid evaluation of genes implicated in human melanoma.Melanoma mutagenesis and aberrant cell signaling.Non-BRAF-targeted therapy, immunotherapy, and combination therapy for melanoma.NRAS-mutant melanoma: current challenges and future prospectKRAS, NRAS and BRAF mutations in colorectal cancer and melanoma.Plasma Circulating Tumor DNA Levels for the Monitoring of Melanoma Patients: Landscape of Available Technologies and Clinical Applications.Mouse melanoma models and cell lines.Histopathological atlas and proposed classification for melanocytic lesions in Tyr::NRas(Q61K) ; Cdkn2a(-/-) transgenic mice.Wild-type KRAS is a novel therapeutic target for melanoma contributing to primary and acquired resistance to BRAF inhibition.The Prognostic Value of HRAS mRNA Expression in Cutaneous Melanoma.Acetylsalicylic Acid Governs the Effect of Sorafenib in RAS- Mutant Cancers.New susceptibility loci for cutaneous melanoma risk and progression revealed using a porcine model.
P2860
Q26781652-33429B1B-134A-4442-B448-FC858ABC1DD1Q27006853-42B92B6D-0D3E-4606-9072-DBF405450F1BQ28078716-88C4E0AD-E498-44A6-AB84-FC54E7C6A86EQ28392156-0C5D07F6-D4F2-4613-B23A-5F25319B7B22Q33664891-81A4014B-CD8F-4FC5-8EF2-DE3F0CAA0866Q33705675-ED545431-7502-4A4C-939C-29134B214D98Q34259205-59CE821C-7430-4F62-92F6-39688ACFEA92Q35878248-D4378E44-95EF-4F20-86E8-23FFC65FEBF0Q36073207-045837BC-197A-458F-A759-8C1FC8F5B4ACQ36130491-3EFF3A02-9047-4372-9322-5CF1A077C19FQ36563659-46F57CFB-EBEE-4E93-A4C1-4D2D3DE53837Q36762792-B028DD33-68C7-4358-BEDD-9618AA3ED658Q36902066-72E6B8BF-943D-4DB9-9CD5-0E427FC05FE2Q36961667-196042F7-D8AD-4BF6-9BDA-5E6D753034FBQ37270065-1CAF8C00-3915-43AC-A181-A5A02772740AQ37689575-76A014EB-AF96-4A19-8FE9-AD7D6CBEB4FEQ37722851-D40FA2A8-5A74-48BD-BE38-4C625FF3828EQ37847257-7F0A488C-899C-4512-B629-B40BFCF582EBQ38146707-4FA6F85E-968C-4939-A9CD-37C6ED0D064CQ38195656-E00357D0-B880-4A4B-A759-89588D5EA235Q38598958-E89BD42B-3838-452D-B20A-D434A8CA3A71Q39078976-451BFD1C-E537-473E-9A6C-BCC7BD9094B9Q39292740-C210AA9F-57C4-4A8C-9E71-C8D69509C0C7Q39640218-EAB5C237-19D6-4FEB-A154-6714F12343CCQ43511598-9B442905-90AA-4139-8E4D-C79B2FD1549BQ47566725-DFACE214-4A5C-4ECA-B0DA-F37D6048578AQ48213688-93C58E2D-1C54-4A0E-BC52-AF28E61E7EB8Q48583910-2D007AD7-5C1D-4D6C-AA4E-D8A7543ADA7CQ55513422-CC76536F-50FE-4093-B6AF-C98F092739BF
P2860
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
A mouse model of melanoma driven by oncogenic KRAS.
@en
type
label
A mouse model of melanoma driven by oncogenic KRAS.
@en
prefLabel
A mouse model of melanoma driven by oncogenic KRAS.
@en
P2093
P2860
P50
P1433
P1476
A mouse model of melanoma driven by oncogenic KRAS.
@en
P2093
Carla Milagre
Felipe C Geyer
Maryou Lambros
Robert Hayward
P2860
P304
P356
10.1158/0008-5472.CAN-09-4254
P407
P577
2010-06-01T00:00:00Z